论文部分内容阅读
目的 评价新一代抗高血压药物科素亚治疗高血压的临床疗效。方法 采用随机双盲试验的方法 ,将 1 0 4例高血压患者随机分成 2组 ,治疗组 52例 ,口服科素亚 50 mg,1次 /d;对照组 52例 ,口服卡托普利 1 2 .5mg,3次 /d,疗程为 6周。用偶测血压及 2 4 h动态血压 (ABPM)评价疗效。结果 治疗组、对照组降压有效率分别为 96%、92 % ,两组间疗效无显著差异 (P >0 .0 5) ,均有较好的降压效果 ,且均能有较好的谷 /峰比值。对照组主要副作用有咳嗽。结论 科素亚是一种安全、有效的长效降压药物
Objective To evaluate the clinical efficacy of a new generation of antihypertensive drug kosia in the treatment of hypertension. Methods One hundred and four patients with hypertension were randomly divided into two groups. The treatment group (52 cases) was treated with Coxsalazine 50 mg once daily, while the control group (52 cases) received captopril 2 .5mg, 3 times / d, treatment for 6 weeks. The curative effect was evaluated by even measuring blood pressure and 24 h ambulatory blood pressure (ABPM). Results The effective rates of antihypertensive treatment in the treatment group and control group were 96% and 92%, respectively. There was no significant difference between the two groups (P> 0.05), and both had better antihypertensive effect, and both had better Valley / peak ratio. The main side effects of the control group cough. Conclusion Cozaar is a safe and effective long-acting antihypertensive drug